Stephens Investment Management Group LLC Grows Position in Icon Plc $ICLR

Stephens Investment Management Group LLC grew its stake in Icon Plc (NASDAQ:ICLR) by 13.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 542,996 shares of the medical research company’s stock after purchasing an additional 62,892 shares during the period. Icon comprises approximately 1.3% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 11th largest holding. Stephens Investment Management Group LLC owned 0.67% of Icon worth $98,945,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Geneos Wealth Management Inc. lifted its position in shares of Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after buying an additional 56 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after buying an additional 56 shares in the last quarter. Signaturefd LLC lifted its position in shares of Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after buying an additional 72 shares in the last quarter. New Wave Wealth Advisors LLC lifted its position in shares of Icon by 5.1% during the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after buying an additional 72 shares in the last quarter. Finally, 1900 Wealth Management LLC lifted its position in shares of Icon by 4.4% during the 4th quarter. 1900 Wealth Management LLC now owns 2,430 shares of the medical research company’s stock valued at $443,000 after buying an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Stock Down 0.6%

Shares of ICLR opened at $116.38 on Friday. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The company has a market capitalization of $9.40 billion, a PE ratio of 15.75, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23. The stock has a fifty day simple moving average of $109.72 and a two-hundred day simple moving average of $144.82. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ICLR. Weiss Ratings lowered Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Jefferies Financial Group set a $135.00 price objective on Icon and gave the company a “buy” rating in a research note on Monday, February 23rd. Barclays reduced their price objective on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, March 9th. Leerink Partners set a $125.00 price objective on Icon in a research note on Monday, May 4th. Finally, Citigroup reduced their price objective on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Icon has a consensus rating of “Hold” and a consensus price target of $149.38.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.